The Middle EAST Burkitt Lymphoma Therapeutics Market was valued at USD 0.25 billion in 2024 and is projected to reach USD 0.55 billion by 2034, registering a CAGR of 8.5%. This growth trajectory is underpinned by several factors, including the rising incidence of Burkitt lymphoma, advancements in therapeutic options, and increasing awareness regarding early diagnosis and treatment. The region...